New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
New approach methodologies (NAMs) can deliver improved chemical safety assessment through the provision of more protective and/or relevant models that have a reduced reliance on animals. Despite the widely acknowledged benefits offered by NAMs, there continue to be barriers that prevent or limit their application for decision-making in chemical safety assessment. These include barriers related to real and perceived scientific, technical, legislative and economic issues, as well as cultural and societal obstacles that may relate to inertia, familiarity, and comfort with established methods, and perceptions around regulatory expectations and acceptance. This article focuses on chemical safety science, exposure, hazard, and risk assessment, and explores the nature of these barriers and how they can be overcome to drive the wider exploitation and acceptance of NAMs. Short-, mid- and longer-term goals are outlined that embrace the opportunities provided by NAMs to deliver improved protection of human health and environmental security as part of a new paradigm that incorporates exposure science and a culture that promotes the use of protective toxicological risk assessments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“…used as a test species in many sectors as part of safety assessment, have a poor true positive human toxicity predictivity rate of only 40%– 65% 13–19 ), yet they are frequently viewed as the “gold standard” and a relevant performance standard to be met by NAMs to ensure similar or higher…”
BackgroundToxicity testing in the 21st century: A vision and a strategy
Gibb, S. (2008) · Reproductive Toxicology · doi:10.1016/j.reprotox.2007.10.013 · Cited by 1,257
A framework for establishing scientific confidence in new approach methodologies
van der Zalm, A. J., Barroso, J., Browne, P., Casey, W., Gordon, J., Henry, T. R., Kleinstreuer, N. C., Lowit, A. B., Perron, M., & Clippinger, A. J. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03365-4 · Cited by 257
Paul Friedman, K., Gagne, M., Loo, L.-H., Karamertzanis, P., Netzeva, T., Sobanski, T., Franzosa, J. A., Richard, A. M., Lougee, R. R., Gissi, A., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfz201 · Cited by 248
Guideline No. 497: Defined Approaches on Skin Sensitisation
OECD (2025) · OECD Guidelines for the Testing of Chemicals, Section 4 · doi:10.1787/b92879a4-en · Cited by 231
Spielmann, H., Hoffmann, S., Liebsch, M., Botham, P., Fentem, J. H., Eskes, C., Roguet, R., Cotovio, J., Cole, T., Worth, A., et al. (2007) · Alternatives to Laboratory Animals · doi:10.1177/026119290703500614 · Cited by 230
Exposure science in the 21st century: a vision and a strategy
Lippmann, M. (2013) · Journal of Exposure Science & Environmental Epidemiology · doi:10.1038/jes.2012.109 · Cited by 229
Nations, U. (2011) · Globally Harmonized System of Classification and Labelling of Chemicals (GHS) · doi:10.18356/4255cc90-en · Cited by 198
Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients
Dent, M., Amaral, R. T., Da Silva, P. A., Ansell, J., Boisleve, F., Hatao, M., Hirose, A., Kasai, Y., Kern, P., Kreiling, R., et al. (2018) · Computational Toxicology · doi:10.1016/j.comtox.2018.06.001 · Cited by 187 · cited 3×
“30–33 NAMs-based risk assessments have also been integrated into international guidelines for safety assessments of cosmetic ingredients, 34 where legislative bans on animal testing are in place for cosmetics in some regions.”
BackgroundMethodMonticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K., & Kadambi, V. J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.006 · Cited by 186
An analysis of the use of animal models in predicting human toxicology and drug safety
Bailey, J., Thew, M., & Balls, M. (2014) · Alternatives to Laboratory Animals · doi:10.1177/026119291404200306 · Cited by 182
Artificial intelligence (AI)—it’s the end of the tox as we know it (and I feel fine)*
Kleinstreuer, N., & Härtung, T. (2024) · Archives of Toxicology · doi:10.1007/s00204-023-03666-2 · Cited by 176 · cited 1×
“25,26 These sorts of approaches could help ensure the NAMs and resulting data are valid to use for decision-making within a given context .”
BackgroundA big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans
Clark, M., & Steger-Hartmann, T. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.04.018 · Cited by 162
A Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products
Baltazar, M. T., Cable, S., Carmichael, P. L., Cubberley, R., Cull, T., Delagrange, M., Dent, M. P., Hatherell, S., Houghton, J., Kukic, P., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa048 · Cited by 151 · cited 1×
“There are also well-documented examples of NAMs used in individual risk assessments both within the consumer goods industry (e.g. coumarin 36 ; phenoxyethanol 37 ; benzophenone-4 38 ) and within other sectors (e.g. chlorothalonil, 39 Captan and Folpet 12,40 ).”
BackgroundSelf-citationAtkins, J. T., George, G. C., Hess, K., Marcelo-Lewis, K. L., Yuan, Y., Borthakur, G., Khozin, S., LoRusso, P., & Hong, D. S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01033-x · Cited by 132
Berggren, E., White, A., Ouedraogo, G., Paini, A., Richarz, A.-N., Bois, F. Y., Exner, T., Leite, S., Grunsven, L. A. V., Worth, A., et al. (2017) · Computational Toxicology · doi:10.1016/j.comtox.2017.10.001 · Cited by 122 · cited 1×
“Here, a tiered and/or iterative approach, as set out in the SEURAT-1 ab initio risk assessment workflow 42 and the ICCR principles on the use of NAMs 34 may help overcome such concerns, such that, at least initially, lower tier NAMs approaches are more conservative than using traditional animal…”
MethodAdverse Outcome Pathways can drive non‐animal approaches for safety assessment
Burden, N., Sewell, F. R., Andersen, M. E., Boobis, A. R., Chipman, J. K., Cronin, M., Hutchinson, T. H., Kimber, I., & Whelan, M. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3165 · Cited by 116 · cited 1×
“22,23 As is true for animal models, it will not bepossibleforasingleNAMtopredictallpossiblehazardsat once, or for a combination of NAMs to cover the whole toxicological space.”
BackgroundSelf-citationBernauer, U., Bodin, L., Chaudhry, Q., Coenraads, P. J., Dušinská, M., Ezendam, J., Gaffet, É., Galli, C. L., Granum, B. B., Panteri, E., et al. (2021) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2021.105052 · Cited by 105
Are Non-animal Systemic Safety Assessments Protective? A Toolbox and Workflow
Middleton, A., Reynolds, J., Cable, S., Baltazar, M. T., Li, H., Bevan, S. J., Carmichael, P. L., Dent, M. P., Hatherell, S., Houghton, J., et al. (2022) · Toxicological Sciences · doi:10.1093/toxsci/kfac068 · Cited by 83 · cited 1×
“27 With this in mind, in addition to exposure considerations such as the dose, frequency, duration and route, there are other factors that potentially impact on the generation of adverse health effects, including for instance development stage and age, diurnal rhythms, co-exposures and…”
BackgroundAvila, A. M., Bebenek, I., Mendrick, D. L., Peretz, J., Yao, J., & Brown, P. C. (2023) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2023.105345 · Cited by 71 · cited 1×
“Within this, the use of NAMs is encouraged wherever possible as outlined in the FDA Modernization Act 2.0 46 with a thorough assessment of gaps and challenges, 47 and in the European Medicines Agency (EMA) workplan.”
MethodInfluentialEvaluation of Variability Across Rat Acute Oral Systemic Toxicity Studies
Karmaus, A. L., Mansouri, K., To, K. T., Blake, B. E., Fitzpatrick, J. M., Strickland, J. A., Patlewicz, G. Y., Allen, D., Casey, W., & Kleinstreuer, N. (2022) · Toxicological Sciences · doi:10.1093/toxsci/kfac042 · Cited by 64 · cited 1×
“21”
Beyond AOPs: A Mechanistic Evaluation of NAMs in DART Testing
Rajagopal, R., Baltazar, M. T., Carmichael, P. L., Dent, M. P., Head, J., Li, H., Müller, I. I., Reynolds, J., Sadh, K., Simpson, W., et al. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.838466 · Cited by 51 · cited 1×
“28”
Eskes, C., Cole, T., Hoffmann, S., et al. (2007) · Alternatives to Laboratory Animals · doi:10.1177/026119290703500608 · Cited by 47 · cited 1×
“Here, the historical animal tests addressed very specific chemically induced adverse health effects seen in humans (corrosion, irritation or skin sensitisation) and the data from the animal tests were subsequently used to determine whether the NAMs approaches were fit-for-purpose 8–11 ).”
MethodApplication of a new approach method (NAM) for inhalation risk assessment
Ramanarayanan, T. S., Szarka, A. Z., Flack, S. L., Hinderliter, P. M., CORLEY, R. A., Charlton, A., Pyles, S., & Wolf, D. C. (2022) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2022.105216 · Cited by 39 · cited 1×
“There are also well-documented examples of NAMs used in individual risk assessments both within the consumer goods industry (e.g. coumarin 36 ; phenoxyethanol 37 ; benzophenone-4 38 ) and within other sectors (e.g. chlorothalonil, 39 Captan and Folpet 12,40 ).”
BackgroundProcedures for the appraisal of the toxicity of chemicals in foods.
LEHMAN, A. J., & Laug, E. P. (1949) · PubMed · Cited by 38
Alépée, N., Adriaens, E., Abo, T., Bagley, D. M., Desprez, B., Hibatallah, J., Mewes, K. R., Pfannenbecker, U., Sala, À., Rompay, A. R. V., et al. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.04.011 · Cited by 38
The future trajectory of adverse outcome pathways: a commentary
Sewell, F. R., Gellatly, N. L., Beaumont, M., Burden, N., Currie, R. A., de Haan, L., Hutchinson, T. H., Jacobs, M. N., Mahony, C., Malcomber, I., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2183-2 · Cited by 32 · cited 1×
“22,23 As is true for animal models, it will not bepossibleforasingleNAMtopredictallpossiblehazardsat once, or for a combination of NAMs to cover the whole toxicological space.”
BackgroundSelf-citationApplication of Defined Approaches for Skin Sensitization to Agrochemical Products
Strickland, J. A., Truax, J. F., Corvaro, M., Settivari, R. S., Henriquez, J. E., McFadden, J., Gulledge, T. V., Johnson, V. J., Gehen, S. C., Germolec, D. R., et al. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.852856 · Cited by 30 · cited 1×
“Here, the historical animal tests addressed very specific chemically induced adverse health effects seen in humans (corrosion, irritation or skin sensitisation) and the data from the animal tests were subsequently used to determine whether the NAMs approaches were fit-for-purpose 8–11 ).”
MethodReproducibility of organ-level effects in repeat dose animal studies
Friedman, K. P., Foster, M. J., Pham, L., Feshuk, M., Watford, S., Wambaugh, J. F., Judson, R., Setzer, R. W., & Thomas, R. S. (2023) · Computational Toxicology · doi:10.1016/j.comtox.2023.100287 · Cited by 26
Blümmel, T., Rehn, J., Mereu, C., Graf, F., Bazing, F., Kneuer, C., Sonnenburg, A., Wittkowski, P., Padberg, F., Bech, K., et al. (2024) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2024.en-8567 · Cited by 25 · cited 1×
“25,26 These sorts of approaches could help ensure the NAMs and resulting data are valid to use for decision-making within a given context .”
Background
Cited by
Toxicity of Magnetic Nanoparticles in Medicine: Contributing Factors and Modern Assessment Methods
Nowak-Jary, J., & Machnicka, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178586 · Cited by 25
Metadata
- Authors
- Sewell, F., Alexander-White, C., Brescia, S., Currie, R. A., Roberts, R., Roper, C., Vickers, C., Westmoreland, C., & Kimber, I.
- Venue
- Toxicology Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-03-01
- Volume
- 13
- Issue
- 2
- Pages
- tfae044-tfae044
- ISSN
- 2045-452X (ISSN-L)
- 2045-4538
- OpenAlex
- W4393204800
- Cited by
- 213
- References
- 30
- FWCI
- 103.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.